Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Schuler

Showing results (191-200 of 297) with videos related to

Pageof 30
Sort By:
Science (New York, N.Y.)|August 16, 2008
Tumor regression in cancer patients by very low doses of a T cell-engaging antibodyRalf Bargou, Eugen Leo, Gerhard Zugmaier, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 19, 2026
<sup>90</sup>Y-FAPI-46 Radiopharmaceutical Therapy in Sarcoma and Other Solid Tumors: An Updated Cohort AnalysisHelena Lanzafame, Ilektra A Mavroeidi, Kim M Pabst, et al.
European Journal of Cancer (Oxford, England : 1990)|April 19, 2021
BRAF mutations and BRAF mutation functional class have no negative impact on the clinical outcome of advanced NSCLC and associate with susceptibility to immunotherapyMarcel Wiesweg, Cedric Preuß, Julia Roeper, et al.
Mucosal Immunology|June 6, 2019
The IL-33/ST2 pathway shapes the regulatory T cell phenotype to promote intestinal cancerEva Pastille, Marie-Hélène Wasmer, Alexandra Adamczyk, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 14, 2022
Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer EntitiesWolfgang P Fendler, Kim M Pabst, Lukas Kessler, et al.
JAMA Oncology|December 14, 2018
Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical TrialDejan Juric, Filip Janku, Jordi Rodón, et al.
Lung Cancer (Amsterdam, Netherlands)|June 16, 2019
First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trialsMartin Schuler, Luis Paz-Ares, Lecia V Sequist, et al.
European Journal of Cancer (Oxford, England : 1990)|December 25, 2021
Treatment with ribociclib shows favourable immunomodulatory effects in patients with hormone receptor-positive breast cancer-findings from the RIBECCA trialCaroline A Peuker, Sarvenaz Yaghobramzi, Corinna Grunert, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|August 4, 2020
Assessment of coronary artery disease during hospitalization for cancer treatmentSimone M Mrotzek, Alessia Lena, Sara Hadzibegovic, et al.
The Patient|November 28, 2017
Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6)Yi-Long Wu, Vera Hirsh, Lecia V Sequist, et al.
Pageof 30

Showing results (191-200 of 297) with videos related to

Sort By:
Pageof 30
Science (New York, N.Y.)|August 16, 2008
Tumor regression in cancer patients by very low doses of a T cell-engaging antibodyRalf Bargou, Eugen Leo, Gerhard Zugmaier, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 19, 2026
<sup>90</sup>Y-FAPI-46 Radiopharmaceutical Therapy in Sarcoma and Other Solid Tumors: An Updated Cohort AnalysisHelena Lanzafame, Ilektra A Mavroeidi, Kim M Pabst, et al.
European Journal of Cancer (Oxford, England : 1990)|April 19, 2021
BRAF mutations and BRAF mutation functional class have no negative impact on the clinical outcome of advanced NSCLC and associate with susceptibility to immunotherapyMarcel Wiesweg, Cedric Preuß, Julia Roeper, et al.
Mucosal Immunology|June 6, 2019
The IL-33/ST2 pathway shapes the regulatory T cell phenotype to promote intestinal cancerEva Pastille, Marie-Hélène Wasmer, Alexandra Adamczyk, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 14, 2022
Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer EntitiesWolfgang P Fendler, Kim M Pabst, Lukas Kessler, et al.
JAMA Oncology|December 14, 2018
Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical TrialDejan Juric, Filip Janku, Jordi Rodón, et al.
Lung Cancer (Amsterdam, Netherlands)|June 16, 2019
First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trialsMartin Schuler, Luis Paz-Ares, Lecia V Sequist, et al.
European Journal of Cancer (Oxford, England : 1990)|December 25, 2021
Treatment with ribociclib shows favourable immunomodulatory effects in patients with hormone receptor-positive breast cancer-findings from the RIBECCA trialCaroline A Peuker, Sarvenaz Yaghobramzi, Corinna Grunert, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|August 4, 2020
Assessment of coronary artery disease during hospitalization for cancer treatmentSimone M Mrotzek, Alessia Lena, Sara Hadzibegovic, et al.
The Patient|November 28, 2017
Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6)Yi-Long Wu, Vera Hirsh, Lecia V Sequist, et al.
Pageof 30